Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer

Henan Cancer Hospital

Status and phase: Unknown; Phase 2

Conditions: Chemotherapy; Maintenance; Extensive Disease; Small Cell Lung Cancer; Adoptive Cellular Immunotherapy

Treatments: Drug: sintilimab maintenance

Study type: Interventional

Funder types: Other

Identifiers

NCT03983759

HenanCH immunotherapy002

Details and patient eligibility

About

Small cell lung cancer is a highly aggressive malignancy. Currently, there is no effective regimen for patients after the progression offirst-line chemotherapy. The prognosis of patients with extensive disease is very poor, and the improved therapeutic efficacy is urgently needed. Most patients with small cell lung cancer have a long history of smoking, and the tumor mutation burden is relatively high, which provides potential for immunological checkpoint inhibitors represented by PD-1 antibodies. A number of studies have shown that chemotherapy combined with adoptive cellular immunotherapy could prolong the survival of patients. This study is a clinical study to explore the efficacy and safety of maintenance therapy with sintilimab after 4-6 cycles of first-line chemotherapy combined with adoptive cellular immunotherapy in patients with advanced small cell lung cancer.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• small cell lung cancer confirmed by pathology
• extensive small cell lung cancer by imaging
• at least one measurable lesion by RECIST 1.1
• ECOG 0-1
• adequate organ function
• no other severe diseases conflicting with this regimen (such as autoimmune diseases, immunodeficiency, organ transplantation, etc)
• no history of other maliganancies
• Women of childbearing period must examinate for a negative pregnancy test within 7 days, use appropriate contraceptive measures during the study and 6 months after the trial.
• agreement to participate in the study and signed informed consent from the patients

Exclusion criteria

• serious infectious diseases four weeks before enrollment
• requirement intermittent use of bronchodilators or medical interventions;
• the use of immunosuppressants before the enrollment, the amount of immunosuppressant used ≥10mg / day oral prednisone for more than 2 weeks;
• severe allergies
• severe mental disorders
• abnormal coagulation function
• previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, severe lung damage, etc.
• other situations considered by investigators not meet the inclusion criteria (including but not limited to symptomatic brain metastases)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

treatment group

Experimental group

Description:

phlebotomation 50ml 1-7 days before chemotherapy for culture of R-CIK cells chemotherapeutic regimen EP or EC as follows: VP-16 100mg/m2 D1-3 plus cisplatin 75mg/m2 D1 or VP-16 100mg/m2 D1-3 plus carboplatin AUC=5 D1 R-CIK cells were transfused back to the patients 2-7 days after the end of chemotherapy, and the amount of R-CIK cells returned each time was about 5×109 three weeks each cycle efficacy evaluated every two cycles patients with the efficay is CR, PR or SD after 4-6 cycles enter the sintilimab maintenance therapy for one year or until the progression of disease, or occurrence of intolerable adverse events. the dose of sintilimab is fixed dose of 200mg every three weeks

Treatment:

Drug: sintilimab maintenance